ClinicalTrials.gg
RecruitingNCT06459271Updated Aug 24, 2026

Feasibility of CALM in Patients With Ovarian Cancer

An interventional study of Managing Cancer And Living Meaningfully (CALM) in Patient Satisfaction and Ovarian Cancer, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 49 studies in Patient Satisfaction with a site in Canada — 6 open to participants now, 9 under way, none of them phase 3. Patient Satisfaction · Canada.

Planned enrollment
33rd of 43
50 · median 101
Started
2024
with 1 other
No phase
41 of 49
5 open now
Registered
43rd of 49
by date
Lead sponsor
4 of 49
University Health Network, Toronto

Among the 49 studies in Patient Satisfaction with a site in Canada, this one is the 33rd largest by planned enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2024, is one of 41 with no phase, and was the 43rd registered.

Patient Satisfaction

882 studies on the registry are indexed under Patient Satisfaction; 205 are open to participants now.

Browse Patient Satisfaction studies →

Open to participants now

6 of the 49 studies in Patient Satisfaction with a site in Canada are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 102 Patient Satisfaction studies recruiting now, 63 (62%) set no upper age limit and 31 (30%) stop at 75 or younger; 14 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Patient Satisfaction with a site in Canada, or all of them as a file.
02

Study summary

The goal of this feasibility trial is to determine the feasibility and acceptability of implementing a brief evidence-based psychotherapeutic intervention, Managing Cancer And Living Meaningfully (CALM), at the time of a new diagnosis and recurrence of ovarian cancer (OC).

The main questions are:

  1. Is it feasible and acceptable to implement CALM for patients with newly diagnosed or recently recurred advanced OC
  2. What is the patient experience of CALM-TF at new diagnosis or recurrence

Participants will be asked to complete questionnaires at baseline and at 3 and 6 months following a diagnosis or recurrence of stage III or IV OC. Participants will also be invited to participate in 3-6 sessions of CALM therapy.

Read the detailed description

While CALM has demonstrated effectiveness in reducing depression, death anxiety and increasing preparation for end of life among patients with advanced cancer later in the illness trajectory, its feasibility and effectiveness in addressing traumatic stress symptoms (TSS) soon after a diagnosis of advanced cancer has not previously been established. Findings of this study could inform the potential development of a larger randomized effectiveness trial. This study will involve a multi-method, single-arm, feasibility trial, approaching a total of 100 OC patients (50 newly diagnosed and 50 recently recurred) at Princess Margaret Cancer Centre (PM). Measurements will be administered at baseline, 3 months and 6 months. Participants who declined to participate in the intervention will be invited to share their reasons for opting out, contributing valuable insights to our records. A subset of purposefully sampled participants will also complete qualitative interviews following the completion of outcome measures at 6 months.

03

Conditions studied

  • Patient Satisfaction
  • Ovarian Cancer

Keywords

  • ovarian cancer
  • psychological care
  • CALM
  • psychotherapeutic intervention
  • psychological distress
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • new diagnosis or recurrence of stage III or stage IV OC;
  • age ≥18 years
  • able to complete outcome measures and engage in CALM in English.

Exclusion criteria

Exclusion Criteria:

  • evidence of cognitive impairment indicated in the medical record, communicated by the OC clinic team, or determined by research staff at recruitment;
  • receiving psychological or psychiatric counseling from the Department of Supportive Care at PM at the time of recruitment.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Newly Diagnosed + Recently Recurred

    n = 50 patients with ovarian cancer (stage III or IV) will be enrolled in the study (25 newly diagnosed and 25 recently recurred).

    Other: Managing Cancer And Living Meaningfully (CALM)

Interventions

  • OtherManaging Cancer And Living Meaningfully (CALM)

    Our team has developed a brief, manualized, individual and couple-based psychotherapeutic intervention for patients living with advanced cancer and their primary caregivers called Managing Cancer and Living Meaningfully (CALM). CALM is a brief supportive-expressive therapy consisting of 3-6 sessions of 30-60 minutes delivered over the course of 3-6 months. This tailored therapy is focused on the most common challenges and concerns facing individuals living with advanced cancer. These four broad content domains are: 1) symptom management and communication with healthcare providers; 2) changes in self and in relationships with close others; 3) sense of meaning and purpose in life; and 4) hopes and fears about the future and mortality. The aim is to offer patients and caregivers reflective space and a supportive environment to reflect on and process the various practical and profound aspects of their life while facing advanced illness.

06

What researchers measure

Primary outcomes

  1. Stanford Acute Stress Reaction Questionnaire (SASRQ)

    The SASRQ is a self-reported DSM-IV correspondent scale to measure a range of symptoms associated with Acute Stress Disorder (ASD), encompassing dissociation, trauma re-experiencing, avoidance behaviours, anxiety, hyperarousal, and functional impairment. The SASRQ consists of 30-items utilizing a 6-point scale that ranges from 0=not experienced to 4=very often experienced. Demonstrating robust psychometric properties, including strong test-retest reliability and consistent evidence of predictive, construct, discriminant, and convergent validity across varied populations, the SASRQ serves as a reliable and valid tool for assessment.

    Time frame: This questionnaire will be administered at all timepoints (baseline, 3 months and 6 months)

  2. Clinical Evaluation Questionnaire (CEQ)-CALM

    The CEQ is a 7-item validated questionnaire, created by our research team to assess the perceived benefit of interactions with health care providers in domains relevant to advanced cancer.

    Time frame: This questionnaire will be administered at 3 months and 6 months only.

Secondary outcomes

  1. Modified Experiences in Close Relationships (ECR-M-16)

    The ECR-M-16 is a validated measure with 16-items, has been thoughtfully adapted to be less time-consuming and alleviate any potential burden for patients who may be physically unwell.

    Time frame: This questionnaire will be administered at baseline.

  2. Condensed Memorial Symptom Assessment Scale (CMSAS)

    The CMSAS CMSAS stands as a straightforward and validated self-report evaluation tool, comprising 14 items. It effectively gauges various aspects such as energy level, dry mouth, appetite, weight loss, pain, nausea, drowsiness etc. These facets are organized into three subscales: physical, psychological and symptom distress.

    Time frame: This questionnaire will be administered at all timepoints (baseline, 3 months and 6 months).

  3. Patient Health Questionnaire (PHQ-9)

    The PHQ-9 is a diagnostic tool used in primary care settings to establish criteria-based diagnoses for depression. PHQ-9 is a 9-tem, self-reported questionnaire which consists of the 9 depression criteria which is highlighted within the DSM-IV. PHQ-9 is particularly favoured due to its concise structure, which efficiently identifies the presence of depressive disorders and is also able to rate the severity of depressive symptoms.

    Time frame: This questionnaire will be administered at all timepoints (baseline, 3 months and 6 months).

  4. Death and Dying Distress Scale (DADDS)

    The DADDS is a tool used to evaluate the distress caused by a patients thoughts on death and dying over the previous two weeks. DADDS is a 15-items questionnaire with the aims of alleviating the fear of death and fostering psychological development (Nissim et al., 2011; Shapiro et al., 2021).The validity of DADDS has been rigorously established, with factor analysis demonstrating distress related to two factors: Finitude and Dying.

    Time frame: This questionnaire will be administered at all timepoints (baseline, 3 months and 6 months).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Feb 2027, 32 months after the start.

Of 368 non-industry interventional studies with no phase under Patient Satisfaction, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 32 months is above that.

Counting every sponsor, half of 370 studies reached it within 12 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2024
First posted
Jun 14, 2024
StartActual
Jun 10, 2024
Primary completionEst.
Feb 2027
CompletionEst.
Jun 2027
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06459271
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
Jun 14, 2024
Start date
Jun 10, 2024
Primary completion
Feb 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Aug 24, 2026

Study contacts

Megan A George, BSc
Contact
megan.george@uhn.ca
6475463114
Anne Rydall, MSc
Contact
anne.rydall@uhn.ca
416-910-7349
Gary M Rodin, MD
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion